We integrate computational chemistry and other advanced technologies to design breakthrough medicines and transform drug development. http://bit.ly/2DThNVN
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $608M
Founded date: 2009
Investors 6
| Date | Name | Website |
| - | Access Bio... | accessbio-... |
| - | RA Capital... | racap.com |
| - | Atlas Vent... | atlasventu... |
| - | Lightstone... | lightstone... |
| 02.10.2022 | Bain Capit... | baincapita... |
| - | SR One | srone.com |
Funding Rounds 6
| Date | Series | Amount | Investors |
| 18.09.2023 | - | $210M | - |
| 13.09.2022 | - | $125M | - |
| 13.07.2021 | - | $105M | - |
| 15.10.2020 | - | $60M | - |
| 05.06.2018 | - | $65M | - |
| 19.03.2015 | Series B | $43M | - |
Mentions in press and media 24
| Date | Title | Description |
| 18.12.2023 | Anagenex and Nimbus Announce a Multi-Target Collaboration to Discover Small Molecule Therapeutics for Multiple Indications | Anagenex and Nimbus Therapeutics (Nimbus) announced they have initiated a research collaboration. Anagenex, a pioneering drug discovery company pairing large-scale data generation with proprietary artificial intelligence (AI), will work clo... |
| 18.09.2023 | Nimbus Therapeutics Secures $210M | BOSTON, MA, Nimbus Therapeutics, a clinical-stage company, announced the closing of a $210 million private financing. >> Click here for more funding data on Nimbus Therapeutics >> To export Nimbus Therapeutics funding data t... |
| 06.09.2023 | Nimbus Therapeutics raises $210 million in one of the larger fundraising rounds this year | Seven months after Nimbus Therapeutics sold an experimental autoimmune disease medicine to Takeda Pharmaceuticals for up to $6 billion, the Boston biotech said Wednesday it has raised $210 million in venture capital to advance its pipeline ... |
| 06.09.2023 | Nimbus Therapeutics Secures $210M Private Financing to Advance Next Wave of Tech-Enabled Small Molecule Medicines | – GV joins the company’s distinguished investor base, validating Nimbus’ computational drug discovery engine and early clinical capabilities – |
| 13.12.2022 | Takeda to Acquire Nimbus Therapeutics’ Highly Selective, Allosteric TYK2 Inhibitor to Address Multiple Immune-Mediated Diseases | – Nimbus to receive $4 billion in upfront cash, and up to $2 billion in commercial milestone payments – |
| 13.09.2022 | Nimbus Therapeutics secures $125M in financing for clinical programs | Nimbus Therapeutics, a developer of medicines through computational drug discovery, announced Monday that it has closed $125 million in private financing. Bain Capital Life Sciences and SV Health Investors led the funding round. The company... |
| 12.09.2022 | Pfizer among investors flooding Nimbus with $125M for TYK2 programs, phase 3 launch | Investors have flooded Nimbus Therapeutics with $125 million in private financing, money that will go toward three clinical inflammatory and autoimmune disorder programs, including a phase 3 psoriasis study. The financing follows a $105 mil... |
| 12.09.2022 | Nimbus Therapeutics Closes $125M Financing | CAMBRIDGE, MA, Nimbus Therapeutics announced the closing of a $125 million private financing. >> Click here for more funding data on Nimbus Therapeutics >> To export Nimbus Therapeutics funding data to PDF and Excel, click h... |
| 15.07.2021 | Nimbus Therapeutics Lands $105M Funding | CAMBRIDGE, MA, Nimbus Therapeutics, a biotechnology company, announced the closing of a $105 million private financing round, led by BVF Partners. >> Click here for more funding data on Nimbus Therapeutics >> To export Nimbu... |
| 13.07.2021 | Nimbus Therapeutics : Announces $105 Million Private Financing to Advance Pipeline Including Multiple Clinical Programs | Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the closing of a $105 million private financing round. The round was led by BVF Partners L... |
Show more